MTOR and neoplasm: Around 40% oncogenic aberrations occurring in genes such as KIT, PIK3CA, MTOR, and NFE2L2 were heterogeneously distributed in sub-clones of ESCC patient tumor tissues, while genetic alterations in TP53, ZNF750, and MLL2 occur during earlier stages and are more predominant 38.